Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon PTH in hypoparathyroidism (China)
NCT05387070Phase 3Completed
- Sponsor
- VISEN Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Jan 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoparathyroidism comparing TransCon PTH with Placebo (2 arms). Primary endpoint: Proportion of subjects achieving normal serum calcium and stopping therapeutic doses of active vitamin D and calcium at 26 weeks. Started Jul 2021; status: completed.
02
Drugs
palopegteriparatide
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT05387070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387070.